Answers are grounded in this paper and cite their sources.
The FDA has granted accelerated approval to pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (combined positive score [CPS] ≥10) as determined by an FDA approved test.
No takes yet. Share an insight, caveat, or question.
Hannah Slater (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: